BioSpace News Archive

Celloram Inc., a dynamic biotech startup based in Cleveland, Ohio and developing novel medicines for cancer and immune disorders, announced today a groundbreaking licensing agreement with French biotech GENFIT SA to advance Celloram’s first-in-class inflammasome inhibitor, CLM-022.

In collaboration with Hackensack University Medical Center and Jersey Shore University Medical Center, Electro Cellular Healthcare Solutions, LLC, an affiliate of The Herrick Company, Inc, announces a new study treating patients with mild to moderate Alzheimer’s Dementia.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the presentation of three new abstracts that demonstrate the real-world impact of the Viz Neuro Suite at the Society of Neurointerventional Surgery (SNIS) Annual Meeting.

The Society for Vascular Surgery, the leading medical organization dedicated to advancing quality in vascular health care, has issued a response to a recent New York Times article detailing allegations of overuse of interventions to treat patients with peripheral vascular disease.

Solve GNE, a Los Angeles based non-profit organization, has raised over $2.5 million and negotiated sponsored research agreements with multiple leading medical researchers to help develop a cure for Hereditary Inclusion Body Myopathy.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H).

MannKind Corporation will release its 2023 second quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM on Monday, August 7, 2023.

Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA) reported second quarter 2023 financial results and business highlights.

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”) today announced that it plans to release unaudited financial results for the second quarter ended June 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, August 14, 2023.

Codexis, Inc., a leading enzyme engineering company, announced the launch of a new mini documentary as part of an ongoing campaign in support of World Health Day.